ConductScience.org, home

Paper92181

Virus augmentation of the antigenicity of tumor cell extracts.

Austin FC and 1 other. Adv Cancer Res, 1979. Cited by 50 papers, by iCite.

Cite this record

ConductScience Library. Virus augmentation of the antigenicity of tumor cell extracts. Papers, record 92181. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/92181

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Virus augmentation of the antigenicity of tumor cell extracts.
PubMed
Journal
Adv Cancer Res
PubMed
Year
1979
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
50
iCite
Relative citation ratio, by iCite
1.27
iCite
Revised in PubMed
2019-10-27
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Austin FCF C
2Boone CWC W

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, NeoplasmMajor topic
Antigens, NeoplasmMajor topic
Antigens, ViralMajor topic
Histocompatibility AntigensMajor topic
NeoplasmsMajor topic
Animals
Antibodies, Viral
Epitopes
Humans
Immunotherapy
Mice
Rats

Source PubMed

Download CSV of topics

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMIDTitleJournalYearIn PapersSource
30061941Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells.Oncol Lett2018https://conductscience.org/library/papers/30061941PubMed
24833054Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.Biology (Basel)2013https://conductscience.org/library/papers/24833054PubMed
20356763Whole tumor antigen vaccines.Semin Immunol2010https://conductscience.org/library/papers/20356763PubMed
10341877Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.Gene Ther1999https://conductscience.org/library/papers/10341877PubMed
7728569Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.Ann Surg Oncol1995https://conductscience.org/library/papers/7728569PubMed
6985248Antigenic variation in cancer metastasis: immune escape versus immune control.Cancer Metastasis Rev1982https://conductscience.org/library/papers/6985248PubMed
6607104Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus.Cancer Immunol Immunother1983https://conductscience.org/library/papers/6607104PubMed
6299231
Susceptibility of Marek's disease lymphoblastoid cell lines to infection with influenza and pseudorabies viruses and the protective effect of immunization with influenza virus-infected lymphoblastoid cells.
Arch Virol1982https://conductscience.org/library/papers/6299231PubMed
6265347Sendai virus infected cells are readily cytolysed by guinea-pig complement without antibody.Immunology1981https://conductscience.org/library/papers/6265347PubMed
6203637Immune recognition of tumor cells in mice infected with Pichinde virus.Cancer Immunol Immunother1984https://conductscience.org/library/papers/6203637PubMed
6088033Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies.Cancer Immunol Immunother1984https://conductscience.org/library/papers/6088033PubMed
3677126Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.Cancer Immunol Immunother1987https://conductscience.org/library/papers/3677126PubMed
3460702
Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.
Cancer Immunol Immunother1986https://conductscience.org/library/papers/3460702PubMed
3359458Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia.Cancer Immunol Immunother1988https://conductscience.org/library/papers/3359458PubMed
3297373Chemical xenogenization of experimental tumors.Cancer Metastasis Rev1987https://conductscience.org/library/papers/3297373PubMed
2598179Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2598179PubMed
2462467Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.Cancer Immunol Immunother1989https://conductscience.org/library/papers/2462467PubMed
2225567Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.Clin Exp Metastasis1990https://conductscience.org/library/papers/2225567PubMed
1561807Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma.World J Surg1992https://conductscience.org/library/papers/1561807PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/92181

GET https://conductscience.org/api/papers/v1/92181/authors